Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16249232 | 0.84 | NR1H2 (0.41) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL6372185 | 0.81 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7475769 | 0.79 | NR1H2 (0.41) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13291563 | 0.79 | NR1H2 (0.38) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16632328 | 0.79 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16249235 | 0.77 | NR1H2 (0.42) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13291543 | 0.75 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16632578 | 0.73 | TRPV3 (0.47) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5851258 | 0.73 | PTGDR (0.56) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL29540425 | 0.73 | NR1H2 (0.39) | NR1H2CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153852-B2 | Indole compounds, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-7098234-B2 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20040180885-A1 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICAL CO., LTD. | 2004-09-16 | — | — | US | disclosed |
| EP-1424325-A1 | INDOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6743793-B2 | DP RECEPTOR ANTAGONIST; PROSTAGLANDIN D | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030176400-A1 | Indole derivatives, process for preparation of the same and use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1262475-A1 | INDOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176400-A1 | Indole derivatives, process for preparation of the same and use thereof | IDO1, KIT, ITCH | NR1H2 260/4885CHRM2 73/4885CHRM4 304/4885 |
| US-20050004096-A1 | Indole derivatives, process for producing the same and drugs containing the same as the active ingredient | IDO1, IDO2, PTGIR | NR1H2 250/4885CHRM2 196/4885CHRM4 546/4885 |
| US-20040180885-A1 | Indole derivatives, process for preparation of the same and use thereof | IDO1, KIT, ITCH | NR1H2 260/4885CHRM2 73/4885CHRM4 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.